Boston, MA, April 03, 2016 --(PR.com
)-- John Doench, Associate Director, Genetic Perturbation Platform, Broad Institute of MIT and Harvard, to speak at GTCbio’s CRISPR & Genome Engineering Conference.
Since joining the Broad Institute in 2009, John Doench has engaged in dozens of collaborations centered on functional genomics. As Associate Director of the Genetic Perturbation Platform, John’s role is to provide expert guidance on the design, execution, and analysis of genetic screens, and have done so with a wide variety of research groups across many areas of biology. Additionally, John has many years of experience in the development and use of functional genomic techniques, first with RNAi and more recently with CRISPR technology for genome-wide loss-of-function screening. As leader of research and development in the Platform, John has stayed on the cutting-edge of newest techniques while also focusing on the reduction-to-practice that is critical for enabling collaboration with a broader community of researchers. Prior to joining the Broad, John Doench received his Ph.D. in biology, training with Phil Sharp, and performed postdoctoral work with Ed Harlow at Harvard Medical School.
Attend the CRISPR & Genome Engineering Conference (May 26-27, 2016 in Boston, MA) to listen to John speak about CRISPR-CAS9 and network with colleagues from industry and academia while discussing the most recent advances in therapeutic applications of genome engineering, discovery and mechanisms of CRISPR systems, and updates on current technologies and techniques.
This conference is part of the Genomics & Big Data Summit and features the following four tracks:
6th Next Generation Sequencing
3rd Metabolomics-Advances & Applications in Human Disease
CRISPR & Genome Engineering
Big Data Bioinformatics
For more information, please visit www.gtcbio.com/CRISPR or contact us using the information below.